Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents

Rishi Sukhija, Wilbert S. Aronow, Chandrasekar Palaniswamy, Tarunjit Singh, Rashmi Sukhija, Kumar Kalapatapu, Diwakar Mohan, Anthony L. Pucillo, Carmine Sorbera, Priyanka Kakar, Melvin B. Weiss, Purshotam Lal, Craig E. Monsen

Research output: Contribution to journalArticle

Abstract

No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown

Original languageEnglish (US)
Pages (from-to)293-296
Number of pages4
JournalAmerican Journal of Cardiology
Volume105
Issue number3
DOIs
StatePublished - Feb 1 2010

Fingerprint

Drug-Eluting Stents
Stents
Renal Insufficiency
Sirolimus
Paclitaxel
Age Groups
Diet Therapy
Mortality
Percutaneous Coronary Intervention
Crowns
Glomerular Filtration Rate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents. / Sukhija, Rishi; Aronow, Wilbert S.; Palaniswamy, Chandrasekar; Singh, Tarunjit; Sukhija, Rashmi; Kalapatapu, Kumar; Mohan, Diwakar; Pucillo, Anthony L.; Sorbera, Carmine; Kakar, Priyanka; Weiss, Melvin B.; Lal, Purshotam; Monsen, Craig E.

In: American Journal of Cardiology, Vol. 105, No. 3, 01.02.2010, p. 293-296.

Research output: Contribution to journalArticle

Sukhija, R, Aronow, WS, Palaniswamy, C, Singh, T, Sukhija, R, Kalapatapu, K, Mohan, D, Pucillo, AL, Sorbera, C, Kakar, P, Weiss, MB, Lal, P & Monsen, CE 2010, 'Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents', American Journal of Cardiology, vol. 105, no. 3, pp. 293-296. https://doi.org/10.1016/j.amjcard.2009.09.031
Sukhija, Rishi ; Aronow, Wilbert S. ; Palaniswamy, Chandrasekar ; Singh, Tarunjit ; Sukhija, Rashmi ; Kalapatapu, Kumar ; Mohan, Diwakar ; Pucillo, Anthony L. ; Sorbera, Carmine ; Kakar, Priyanka ; Weiss, Melvin B. ; Lal, Purshotam ; Monsen, Craig E. / Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents. In: American Journal of Cardiology. 2010 ; Vol. 105, No. 3. pp. 293-296.
@article{0960f5775a81443a8c09d0b9fdcbf016,
title = "Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents",
abstract = "No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17{\%}) of 287 patients in the PES group (mean age 71 ± 11 years, 55{\%} men) and in 31 (22{\%}) of 141 patients in the SES group (mean age 71 ± 12 years, 53{\%} men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1{\%} vs 8.5{\%}, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown",
author = "Rishi Sukhija and Aronow, {Wilbert S.} and Chandrasekar Palaniswamy and Tarunjit Singh and Rashmi Sukhija and Kumar Kalapatapu and Diwakar Mohan and Pucillo, {Anthony L.} and Carmine Sorbera and Priyanka Kakar and Weiss, {Melvin B.} and Purshotam Lal and Monsen, {Craig E.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.amjcard.2009.09.031",
language = "English (US)",
volume = "105",
pages = "293--296",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents

AU - Sukhija, Rishi

AU - Aronow, Wilbert S.

AU - Palaniswamy, Chandrasekar

AU - Singh, Tarunjit

AU - Sukhija, Rashmi

AU - Kalapatapu, Kumar

AU - Mohan, Diwakar

AU - Pucillo, Anthony L.

AU - Sorbera, Carmine

AU - Kakar, Priyanka

AU - Weiss, Melvin B.

AU - Lal, Purshotam

AU - Monsen, Craig E.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown

AB - No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown

UR - http://www.scopus.com/inward/record.url?scp=74049125651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049125651&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.09.031

DO - 10.1016/j.amjcard.2009.09.031

M3 - Article

VL - 105

SP - 293

EP - 296

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -